Metastatic Cervical Cancer
Showing 1 - 25 of >10,000
Cadonilimab in Recurrent or Metastatic Cervical Cancer
Not yet recruiting
- Recurrent or Metastatic Cervical Cancer
- (no location specified)
Nov 23, 2023
AK104 Combined With I-125 Brachytherapy for Recurrent or
Not yet recruiting
- Cervical Cancer
- Iodine-125 particle brachytherapy
- AK104
- (no location specified)
Sep 25, 2023
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,
Not yet recruiting
- Cervical Cancer
- +2 more
- PRGN-2009 plus Pembrolizumab
- Pembrolizumab alone
-
Bethesda, MarylandNational Institute of Health
Nov 27, 2023
Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)
Not yet recruiting
- Persistent, Recurrent, or Metastatic Cervical Cancer
- GLS-010
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Apr 4, 2023
Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)
Not yet recruiting
- Metastatic Cervical Cancer
- (no location specified)
Jan 31, 2023
Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)
Not yet recruiting
- Uterine Cervical Neoplasms
- +5 more
- Cadonilimab
- Nab paclitaxel
- (no location specified)
Apr 9, 2023
Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)
Not yet recruiting
- Cervical Cancer
- TQB2868 injection
- +4 more
-
Chongqing, Chongqing, China
- +1 more
Aug 17, 2023
Serplulimab in 2L and Above Treatment of Cervical Cancer
Recruiting
- Cervical Cancer
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
May 30, 2023
METASTATIC CERVICAL CANCER Trial (QL1706, Placebo)
Recruiting
- METASTATIC CERVICAL CANCER
- QL1706
- +3 more
-
Chongqing, Chongqing, China
- +2 more
Nov 24, 2022
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)
Not yet recruiting
- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- SG001 injection
- +5 more
- (no location specified)
Jan 27, 2023
Cervical Cancer Trial in Xi'an (Caldonirimab and Nimotuzumab)
Active, not recruiting
- Cervical Cancer
- Caldonirimab and Nimotuzumab
-
Xi'an, Shaanxi, ChinaThe First Affiliated Hospital of Xi'an Jiao Tong University
Oct 31, 2022
Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)
Not yet recruiting
- Cervical Cancer
- Disitamab Vedotin
- Zimberelimab
-
Bengbu, Anhui, China
- +11 more
Nov 23, 2023
Recurrent or Metastatic Cervical Cancer Trial in Shanghai (SHR-1210, SHR-1020, Physician's choice chemo)
Active, not recruiting
- Recurrent or Metastatic Cervical Cancer
- SHR-1210
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 14, 2022
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer Trial (VB10.16, Atezolizumab Injection [Tecentriq],
Not yet recruiting
- HPV-Related Cervical Carcinoma
- +2 more
- VB10.16
- +2 more
- (no location specified)
Oct 24, 2023
Cervical Cancer, Metastatic Cervical Cancer Trial in Washington, Hackensack (Pembrolizumab, Lenvatinib)
Recruiting
- Cervical Cancer
- Metastatic Cervical Cancer
-
Washington, District of Columbia
- +2 more
Jul 26, 2022
Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer Trial in Mobile (Cabozantinib 40 MG oral once a day,
Terminated
- Cervical Cancer
- +3 more
- Cabozantinib 40 MG oral once a day
- Pembrolizumab 200 mg IV every 3 weeks
-
Mobile, AlabamaUniversity of South Alabama Mitchell Cancer Institute
Jun 3, 2022
Cervical Cancer Trial in Hangzhou (Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin)
Recruiting
- Cervical Cancer
- Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Jul 12, 2022
Cervical Cancer Trial in Guangzhou (QL1706)
Recruiting
- Cervical Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 23, 2022
Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix, Cervical Cancer Trial in Dallas (Ultra-fractionated
Recruiting
- Stage IV Cervical Cancer FIGO 2018
- +3 more
- Ultra-fractionated radiation therapy
-
Dallas, TexasUT Southwestern Medical Center
Apr 29, 2022
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
Retrospective Cervical Cancer Oligo States Multicentre Outcomes
Not yet recruiting
- Cancer, Cervical
- +2 more
- Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)
- (no location specified)
Nov 28, 2023